Tyromotion Competitors

KUKA AG is an internationally active company with sales of around 3.5 billion euro. Every day, roughly 14,200 KUKA employees at our headquarters in Augsburg and around the world work to ensure that we remain one of the world’s leading suppliers of intelligent automation solutions. Our international customers come from, among other sectors, the automotive industry and general industry. KUKA offers you everything from a single source: from the individual components to fully automated systems. Link to imprint: https://www.kuka.com/imprint Data Protection Policy: https://www.kuka.com/privacy

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company’s first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in Richmond, California International Offices: Ekso Bionics Europe GmbH Friesenweg 20 Hamburg, 22763 Germany Tel: +49 40 800 4049 20

CureMetrix is committed to the advancement of technology that improves disease detection and survival rates worldwide. Our AI-based products and research are focused on leveraging artificial intelligence and deep learning to develop the next generation of medical image analysis technology that radiologists and patients can confidently rely on. Today, our powerful image analysis platform is an adjunct, precision tool for mammography. Our goal is to equip radiologists with the objective, data-driven answers they need to support patients and their healthcare team as they make decisions about their health. At CureMetrix, we believe that providing radiologists with the most advanced technology to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs, and increased assurance that patients are getting the highest standard of care available from screening. Over the last 10 years since our founding in 2014, we have focused on building products with extremely high efficacy that are easy to install, operate within existing clinical workflows, and minimize extra steps from radiologists and patients. CureMetrix has partnered with practicing radiologists, cardiologists, and esteemed institutions around the world to collect over 5 million images to train and validate our algorithms. From breast cancer to heart disease to kidney disease we believe that AI can be used to improve outcomes for patients and extend the impact and value of screening programs globally.